Highlights Mesoblast Limited quotes new securities on the ASX amounting to 7 255 000 ordinary fully paid shares The new securities are part of an employee incentive scheme Mesoblast operates in the biotechnology sector focusing on cellular medicines f ...
Mesoblast is an Australia-based regenerative medicine company that develops allogeneic cellular medicines for the treatment of inflammatory and cardiovascular diseases.